<DOC>
	<DOCNO>NCT02829853</DOCNO>
	<brief_summary>Major impact air pollution lung diseases granulomatous disease mainly sarcoidosis . Understanding respective role inorganic / nanoparticles genetic background chronic disease major challenge management patient prevention strategy . Granulomas characterize giant epithelioid multinucleated cell , reflect severe disturbance immunological pathway induce toxic exposure genetic predisposition . Previous study demonstrate professional environmental context acute exposure ( World Trade Center disaster ) micro/nanoparticles pathogenic impact sharp increase sarcoidosis . Sarcoidosis multifactorial disease occur genetically vulnerable context . Many gene variant link increase odds-ratio disease , BTNL2 , CCDC88B , ANNEXIN A11 involve regulation T-cell activation maturation pathway . We contribute since 2008 national cohort ( GSF , 28 center ) ≈ 800 sarcoidosis patient familial sporadic presentation disease . This collection exceptional ( worldwide unique ) tool implementation exhaustive clinical database sarcoidosis , model disease evolution identification clinical / genetic criterion differentiate sporadic familial form . The main goal project : 1 . Completion genetic data order establish pattern gene variant segregate familial form disease , compare sporadic one . This do WES ( WHOLE EXOME ) analysis previously collect DNA sample . The informed consent patient include information BTNL2 gene , already test since 2008 , relate gene connect immune pathway , thus allow unambiguous information research finality project . 2 . Completion clinical data patient , cooperation GSF network , management database establish since 2008 . The data collect commonly detail normal follow-up patient . The project include new intervention patient ( neither radiological invasive test ) . 3 . Specific biological study might do white blood cell patient , might need case new blood sampling , patient first degree relate healthy control . Theses specific study present ethical committee ( CCP ) order validate feasibility term 'new intervention ' cohort . The sample collect volume classical blood sampling ( 2*7 ml ) . 4 . Any project , submit GSF network need specific registration ethical committee validation .</brief_summary>
	<brief_title>Clinical Genetic Study Familial Sarcoidosis ( SARCFAM )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoidosis</mesh_term>
	<criteria>patient affect sarcoidosis , define clinical criterion : chest Xray staging , pulmonary function test , biological variable : serum calcium creatinine , bronchial alveolar lavage cell count available , histological confirmation granuloma biopsy . The disease may express initially uveitis , cutaneous anatomical site involvement , must also confirm sarcoidosisrelated granuloma competent pathologist . Any disease suggest sarcoidosis express similar symptom , ex . hilar lymphadenopathy , form uveitis , restrictive pulmonary syndrome .. etc … . Any patient followup available 8 year program GSF SARCFAM age &lt; 8 year old &gt; 80 year old</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>SARCOIDOSIS</keyword>
	<keyword>GRANULOMA DISEASES</keyword>
	<keyword>GENETICS</keyword>
	<keyword>PREDISPOSITION</keyword>
	<keyword>EXOME ( WES-NGS )</keyword>
</DOC>